Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 11, Novembre 2013
Page(s) 985 - 990
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20132911014
Publié en ligne 20 novembre 2013
  1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010 ; 327 : 291–295. [CrossRef] [PubMed] [Google Scholar]
  2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011 ; 480 : 480–489. [CrossRef] [PubMed] [Google Scholar]
  3. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007 ; 13 : 552–559. [CrossRef] [PubMed] [Google Scholar]
  4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010 ; 140 : 883–899. [CrossRef] [PubMed] [Google Scholar]
  5. Chalmin F, Mignot G, Ghiringhelli F. Cellules myéloïdes suppressives et cancer : une nouvelle cible thérapeutique. Med Sci (Paris) 2010 ; 26 : 576–579. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Finn OJ. Cancer immunology. N Engl J Med 2008 ; 358 : 2704–2715. [CrossRef] [PubMed] [Google Scholar]
  7. Guha M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 2012 ; 11 : 503–505. [CrossRef] [PubMed] [Google Scholar]
  8. Galluzzi L, Vacchelli E, Eggermont A, et al. Trial watch : experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 ; 1 : 699–716. [CrossRef] [PubMed] [Google Scholar]
  9. Heldwein KA, Liang MD, Andresen TK, et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol 2003 ; 74 : 277–286. [CrossRef] [PubMed] [Google Scholar]
  10. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008 ; 222 : 357–368. [CrossRef] [PubMed] [Google Scholar]
  11. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012 ; 13 : 343–351. [CrossRef] [PubMed] [Google Scholar]
  12. Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 2010 ; 107 : 21635–21640. [CrossRef] [Google Scholar]
  13. Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011 ; 108 : 9601–9606. [CrossRef] [Google Scholar]
  14. Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010 ; 207 : 1045–1056. [CrossRef] [PubMed] [Google Scholar]
  15. Goutagny N, Estornes Y, Hasan U, et al. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012 ; 7 : 29–54. [CrossRef] [PubMed] [Google Scholar]
  16. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011 ; 470 : 543–547. [CrossRef] [PubMed] [Google Scholar]
  17. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007 ; 7 : 179–190. [CrossRef] [PubMed] [Google Scholar]
  18. Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012 ; 150 : 606–619. [CrossRef] [PubMed] [Google Scholar]
  19. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007 ; 13 : 1050–1059. [CrossRef] [PubMed] [Google Scholar]
  20. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009 ; 15 : 1170–1178. [CrossRef] [PubMed] [Google Scholar]
  21. Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013 ; 19 : 57–64. [CrossRef] [PubMed] [Google Scholar]
  22. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007 ; 449 : 419–426. [CrossRef] [PubMed] [Google Scholar]
  23. Zhang X, Majlessi L, Deriaud E, et al. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009 ; 31 : 761–771. [CrossRef] [PubMed] [Google Scholar]
  24. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006 ; 440 : 808–812. [CrossRef] [PubMed] [Google Scholar]
  25. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005 ; 433 : 887–892. [CrossRef] [PubMed] [Google Scholar]
  26. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010 ; 10 : 785–794. [CrossRef] [PubMed] [Google Scholar]
  27. Skoberne M, Yewdall A, Bahjat K, et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest 2008 ; 118 : 3990–4001. [CrossRef] [PubMed] [Google Scholar]
  28. Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003 ; 4 : 1247–1253. [CrossRef] [PubMed] [Google Scholar]
  29. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011 ; 477 : 592–595. [CrossRef] [PubMed] [Google Scholar]
  30. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012 ; 4 : 120ra116. [CrossRef] [Google Scholar]
  31. Jamilloux Y, Henry T. Les inflammasomes : plates-formes de l’immunité innée. Med Sci (Paris) 2013 ; 29 : 975–984. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Tartour E, Sandoval F, Bennefoy JY, Fridman WH. Immunothérapie des cancers. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Jobin C. Microbiome : un nouveau facteur de risque de cancer colorectal ? Med Sci (Paris) 2013 ; 29 : 582–585. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Apetoh L, Ghiringhelli F, Zitvogel. La calréticuline détermine l’immunogénicité de la chimiothérapie et de la radiothérapie anti-tumorales. Med Sci (Paris) 2007 ; 23 : 257–258. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.